A5086545572- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Lung Cancer Treatments and Mutations
- Urinary and Genital Oncology Studies
- PARP inhibition in cancer therapy
- Colorectal and Anal Carcinomas
- PI3K/AKT/mTOR signaling in cancer
- Cancer Genomics and Diagnostics
- Radiopharmaceutical Chemistry and Applications
- Nutrition and Health in Aging
- Immunotherapy and Immune Responses
- Radio Frequency Integrated Circuit Design
- Cancer, Hypoxia, and Metabolism
- Urological Disorders and Treatments
- Head and Neck Cancer Studies
- Hormonal and reproductive studies
- Urologic and reproductive health conditions
- Colorectal Cancer Treatments and Studies
- Robotic Locomotion and Control
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Esophageal Cancer Research and Treatment
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
Fairview Health Services
2023-2025
University of Minnesota
2014-2023
Patan Academy of Health Sciences
2023
Fairview Ridges Hospital
2018
Palmetto Hematology Oncology
2014
University of Minnesota Medical Center
2013
Minnesota Oncology
2012
University of Rhode Island
2001-2007
University of Tennessee at Knoxville
2006
North Central College
2006
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported . CheckMate 274 is a phase III, randomized, double-blind trial of adjuvant nivolumab versus placebo muscle-invasive...
LBA443 Background: The 2 primary endpoints of the CheckMate 274 trial were met as nivolumab (NIVO) improved disease-free survival (DFS) versus placebo (PBO) in intent-to-treat (ITT) population and patients with tumor programmed death ligand 1 (PD-L1) expression ≥ 1%. We report extended follow-up data. Methods: is a phase 3, double-blind adjuvant NIVO PBO for high-risk muscle-invasive urothelial carcinoma (MIUC) (bladder, ureter, or renal pelvis) after radical resection. Patients randomly...
Abstract Background : Using the Academy of Nutrition and Dietetics American Society for Parenteral Enteral (Academy/ASPEN) Consensus malnutrition definition, we estimated prevalence in a sample individuals with head neck cancer (HNC) compared it Patient‐Generated Subjective Global Assessment (PG‐SGA). We also investigated utility 50‐kHz phase angle (PA) 200‐kHz/5‐kHz impedance ratio (IR) to identify malnutrition. Materials Methods Nineteen (18 males, 1 female) scheduled undergo...
This pilot study evaluated nutrition status and health-related quality of life (HRQOL) outcomes among outpatients with head neck cancer (HNC). Data were collected from 19 patients (18 males, 1 female) during 3 time points: once before chemoradiotherapy (CRT) initiation months after CRT. Nutrition was using the Scored Patient-Generated Subjective Global Assessment (PG-SGA). Malnutrition defined as PG-SGA stage B (moderate/suspected malnutrition) or C (severely malnourished). HRQOL assessed...
3066 Background: The indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism exploited by tumors in order to prevent and defeat anti-tumor immunity. Sipuleucel-T has overcome this tumor mediated anergy only part its ex-vivo sensitization. Small-molecule inhibitors of the IDO pathway, such as indoximod, are an increasingly validated class potential cancer therapeutics. We tested hypothesis whether targeting indoximod will inhibit Treg abrogate tumor-mediated...
658 Background: In the phase 3, randomized, double-blind CheckMate 274 trial, adjuvant NIVO demonstrated statistically significant and clinically meaningful disease-free survival (DFS) benefit vs PBO in pts with high-risk MIUC after radical surgery (RS) ± prior neoadjuvant cisplatin-based chemotherapy (NAC). With extended 3-y median follow-up, continued improvements DFS were seen primary efficacy populations (intent-to-treat [ITT], tumor programmed death ligand 1 [PD-L1] expression ≥ 1%) MIBC....
The majority of breast cancers express the estrogen receptor and depend on estradiol (E2) for their growth. Hormonal therapy aims at depriving signaling either by using selective modulators (SERM)–-that interfere with binding E2 to its (ER)–-or aromatase inhibitors (AI)–-that block aromatase-dependent synthesis E2. While SERMs are recommended both pre- post-menopausal patients, AIs indicated only patients. For past 20 years, SERM tamoxifen has been considered “gold standard” treatment...
Developing patient derived models from individual tumors that capture the biological heterogeneity and mutation landscape in advanced prostate cancer is challenging, but essential for understanding tumor progression delivery of personalized therapy metastatic castrate resistant stage. To demonstrate feasibility developing xenograft this stage, we present a case study wherein xenografts were metastases progressing on androgen deprivation prior to initiating pre-chemotherapy enzalutamide...
Investigate whether adjuvant everolimus, an mTOR inhibitor, improves progression-free survival (PFS) in advanced-stage head and neck squamous cell carcinoma (HNSCC) provide outcomes related to correlative biological factors associated with disease control.This was a prospective, randomized, double-blind phase II trial of patients HNSCC from 13 institutions who were confirmed disease-free post-definitive therapy enrolled between December 2010 March 2015. Patients received everolimus or...
559 Background: Renal cell carcinoma (RCC) tumor vasculature is abnormal and does not provide nutritive blood flow, which results in regions of hypoxia. This hypoxia contributes to the immune tolerance cells by impeding homing cytotoxic T into parenchyma. In addition, angiogenesis enhances activity myeloid-derived suppressor (MDSC) tumor-associated macrophages (TAM) that suppress innate anti-cancer immunity. It has been demonstrated preclinical models antiangiogenic therapy decreased number...
The Src pathway in activated about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity dasatinib 37 patients with advanced, previously treated NSCLC. Among 29 who underwent pre-treatment biopsy for RNA biomarker analysis, 25 were 70 mg twice daily. There no responses. Five discontinued treatment due to toxicity. Three had minor biopsy-related pneumothoraces. Given lack responses, biomarkers analyzed. daily does not have nor...
TPS388 Background: Up to 25% of patients with advanced prostate cancer, including mCRPC, have a deleterious germline or somatic mutation in BRCA1, BRCA2, ATM another homologous recombination (HR) DNA repair gene that can serve as molecular marker select those who may respond poly(ADP-ribose) polymerase inhibitors (PARPis). PARPis are lethal cells HRD, and PARPi treatment has shown preliminary evidence an antitumor effect mCRPC harbor HR (Mateo et al. N Engl J Med. 2015;373:1697-708). These...
To evaluate the activity of interleukin-2 (IL-2) in combination with allogeneic large multivalent immunogen (LMI) vaccine, prepared by immobilizing SK23-CD80 melanoma cell line plasma membrane on 5-μm-diameter silica beads, patients melanoma.Twenty-one metastatic were randomly assigned to an IL-2 alone control group or plus LMI vaccine treatment group. The primary objective was progression-free survival (PFS) each Secondary clinical objectives included median overall (OS) and 1- 2-year rates...
Pazopanib is a tyrosine kinase inhibitor predominantly acting on tumor endothelium, and ixabepilone semisynthetic analog of epothilone B that promotes microtubule stabilization inducing endothelial cell apoptosis. The purpose this study was to determine the optimal tolerated dose (OTD) combination pazopanib for treatment metastatic previously treated solid tumors.Dose escalation started at 32 mg/m increased 40 mg/m. administered initially 400 mg escalated 200 increments up 800 mg....
2-Amino-α-carboline (AaC, 2-amino-9H-pyrido[2,3-b]indole) is a genotoxic carcinogen produced by cooking of protein-containing foods and combustion biomaterial. Humans are chronically exposed to low levels AaC through (grilled or pan-fried meats), drinking water, smoke inhalation (cigarette/wood smoke, diesel exhaust). We report herein 17 metabolites formed in vivo male Sprague−Dawley rats (from bile, urine, plasma) situ rat hepatocytes human HepG2 liver tumor cells. confirmed several...
79 Background: Rucaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), is approved in the US as monotherapy for BRCA1/2 mutated mCRPC that has been treated with androgen receptor (AR)-directed therapy and taxane. In previous studies, synthetic lethality was observed combination of AR-directed (eg, enzalutamide) PARPi, independent DNA-damage repair gene defects. The potential drug-drug interaction between rucaparib enzalutamide recognized strong clinical inducer CYP3A4, mediator formation...
You have accessJournal of UrologyCME1 May 2022PD10-01 DISEASE-FREE SURVIVAL WITH LONGER FOLLOW-UP FROM THE CHECKMATE 274 TRIAL OF ADJUVANT NIVOLUMAB IN PATIENTS AFTER SURGERY FOR HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA Matthew Galsky, Johannes Alfred Witjes, Jürgen E. Gschwend, Michael Schenker, Begoña P. Valderrama, Yoshihiko Tomita, Aristotelis Bamias, Thierry Lebret, Shahrokh F. Shariat, Se Hoon Park, Mads Agerbaek, Gautam Jha, Frank Stenner Stenner, Sandra Collette, Keziban...
5071 Background: Best treatment of mCSPC involves doublet therapy (ADT + novel hormonal agent) or triplet hormone docetaxel); however, opportunity remains for further improvement. Studies show that homologous recombination repair (HRR) gene mutations are enriched in metastatic prostate cancer, and may portend resistance to docetaxel. CASCARA tested quadruplet cabazitaxel/carboplatin abiraterone) high-volume mCSPC, aiming enhance PSA responses decrease progression at 1 year. Methods: This...